From the Department of Anesthesiology and Critical Care Medicine.
Armstrong Institute for Patient Safety and Quality, The Johns Hopkins Medical Institutions, Baltimore, Maryland.
Anesth Analg. 2020 Dec;131(6):1852-1861. doi: 10.1213/ANE.0000000000005152.
Cardiac anesthetics rely heavily on opioids, with the standard patient receiving between 70 and 105 morphine sulfate equivalents (MSE; 10-15 µg/kg of fentanyl). A central tenet of Enhanced Recovery Programs (ERP) is the use of multimodal analgesia. This study was performed to assess the association between nonopioid interventions employed as part of an ERP for cardiac surgery and intraoperative opioid administration.
This study represents a post hoc secondary analysis of data obtained from an institutional ERP for cardiac surgery. Consecutive patients undergoing cardiac surgery received 5 nonopioid interventions, including preoperative gabapentin and acetaminophen, intraoperative dexmedetomidine and ketamine infusions, and regional analgesia via serratus anterior plane block. The primary objective, the association between intraoperative opioid administration and the number of interventions provided, was assessed via a linear mixed-effects regression model. To assess the association between intraoperative opioid administration and postoperative outcomes, patients were stratified into high (>50 MSE) and low (≤50 MSE) opioids, 1:1 propensity matched based on 15 patients and procedure covariables and assessed for associations with postoperative outcomes of interest. To investigate the impact of further opioid restriction, ultralow (≤25 MSE) opioid participants were then identified, 1:3 propensity matched to high opioid patients, and similarly compared.
A total of 451 patients were included in the overall analysis. Analysis of the primary objective revealed that intraoperative opioid administration was inversely related to the number of interventions employed (estimated -7.96 MSE per intervention, 95% confidence interval [CI], -9.82 to -6.10, P < .001). No differences were detected between low (n = 136) and high (n = 136) opioid patients in postoperative complications, postoperative pain scores, time to extubation, or length of stay. No differences were found in outcomes between ultralow (n = 63) and high (n = 132) opioid participants.
Nonopioid interventions employed as part of an ERP for cardiac surgery were associated with a reduction of intraoperative opioid administration. Low and ultralow opioid use was not associated with significant differences in postoperative outcomes. These findings are hypothesis-generating, and future prospective studies are necessary to establish the role of opioid-sparing strategies in the setting of cardiac surgery.
心脏麻醉主要依赖于阿片类药物,标准患者接受的硫酸吗啡当量(MSE)在 70 至 105 之间(10-15 µg/kg 芬太尼)。增强恢复计划(ERP)的一个基本原则是使用多模式镇痛。这项研究旨在评估作为心脏手术 ERP 一部分的非阿片类干预措施与术中阿片类药物给药之间的关联。
这是一项对心脏手术机构 ERP 获得的数据进行的事后二次分析研究。连续接受心脏手术的患者接受了 5 种非阿片类干预措施,包括术前加巴喷丁和对乙酰氨基酚、术中右美托咪定和氯胺酮输注以及通过前锯肌平面阻滞进行区域镇痛。通过线性混合效应回归模型评估术中阿片类药物给药与提供的干预措施数量之间的关联。为了评估术中阿片类药物给药与术后结果之间的关联,根据 15 名患者和程序协变量对患者进行高低(>50 MSE)阿片类药物分层,并对术后感兴趣的结果进行评估。为了研究进一步限制阿片类药物的影响,然后确定了超低(≤25 MSE)阿片类药物参与者,将其与高阿片类药物患者按 1:3 进行倾向匹配,并进行类似比较。
共有 451 名患者纳入总体分析。对主要目标的分析表明,术中阿片类药物给药与所采用的干预措施数量呈负相关(估计每干预措施减少 7.96 MSE,95%置信区间[CI],-9.82 至-6.10,P<.001)。低(n=136)和高(n=136)阿片类药物患者在术后并发症、术后疼痛评分、拔管时间或住院时间方面无差异。超低(n=63)和高(n=132)阿片类药物患者在结局方面无差异。
作为心脏手术 ERP 的一部分的非阿片类干预措施与术中阿片类药物给药的减少有关。低和超低阿片类药物的使用与术后结果无显著差异。这些发现是产生假说的,需要进一步前瞻性研究来确定心脏手术中阿片类药物节约策略的作用。